Keigo Yorozu

1.3k total citations
52 papers, 1.0k citations indexed

About

Keigo Yorozu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Keigo Yorozu has authored 52 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Keigo Yorozu's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). Keigo Yorozu is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). Keigo Yorozu collaborates with scholars based in United States, Japan and Switzerland. Keigo Yorozu's co-authors include Mitsue Kurasawa, Koh Furugaki, Kaori Fujimoto-Ouchi, Yoriko Yamashita‐Kashima, Mieko Yanagisawa, Toshiki Iwai, Masamichi Sugimoto, Kaname Yamamoto, Yoichiro Moriya and Shigeyuki Iijima and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Keigo Yorozu

50 papers receiving 983 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keigo Yorozu United States	18	566	289	285	176	155	52	1.0k
Tatsunori Shimoi Japan	16	775 1.4×	422 1.5×	229 0.8×	243 1.4×	81 0.5×	105	1.2k
Qingfang Li China	17	336 0.6×	222 0.8×	437 1.5×	98 0.6×	175 1.1×	37	1.0k
Sara Cresta Italy	20	597 1.1×	461 1.6×	422 1.5×	67 0.4×	142 0.9×	55	1.3k
Rosa Fonti Italy	23	560 1.0×	276 1.0×	489 1.7×	387 2.2×	122 0.8×	65	1.6k
Sertaç Yazıcı Türkiye	18	495 0.9×	379 1.3×	459 1.6×	94 0.5×	158 1.0×	56	1.2k
Inga Grünewald Germany	15	443 0.8×	321 1.1×	304 1.1×	85 0.5×	90 0.6×	36	936
Rebecca Moroose United States	9	747 1.3×	357 1.2×	191 0.7×	217 1.2×	59 0.4×	23	1.0k
Riki Okita Japan	20	621 1.1×	395 1.4×	205 0.7×	123 0.7×	434 2.8×	79	1.2k
Preston D. Steen United States	18	579 1.0×	329 1.1×	259 0.9×	37 0.2×	72 0.5×	47	1.0k
Corrine Zarwan United States	13	691 1.2×	200 0.7×	321 1.1×	47 0.3×	226 1.5×	27	1.1k

Countries citing papers authored by Keigo Yorozu

Since Specialization

Citations

This map shows the geographic impact of Keigo Yorozu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keigo Yorozu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keigo Yorozu more than expected).

Fields of papers citing papers by Keigo Yorozu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keigo Yorozu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keigo Yorozu. The network helps show where Keigo Yorozu may publish in the future.

Co-authorship network of co-authors of Keigo Yorozu

This figure shows the co-authorship network connecting the top 25 collaborators of Keigo Yorozu. A scholar is included among the top collaborators of Keigo Yorozu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keigo Yorozu. Keigo Yorozu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yorozu, Keigo, et al.. (2024). PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model. Clinical & Experimental Metastasis. 41(6). 909–924. 3 indexed citations

Serizawa, Kenichi, Shota Miyake, Keigo Yorozu, et al.. (2023). Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice. Journal of Neuroimmunology. 380. 578109–578109. 9 indexed citations

Yorozu, Keigo, Mitsue Kurasawa, Yuka Nakamura, et al.. (2022). Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection. Pathology International. 73(1). 39–44. 2 indexed citations

Wakita, Daiko, et al.. (2021). PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion. Clinical & Experimental Metastasis. 39(2). 335–344. 2 indexed citations

Iwai, Toshiki, Masamichi Sugimoto, Namrata S. Patil, et al.. (2021). Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab. Scientific Reports. 11(1). 13912–13912. 13 indexed citations

Sasaki, Yusuke, et al.. (2019). T2∗ Relaxation Time Obtained from Magnetic Resonance Imaging of the Liver Is a Useful Parameter for Use in the Construction of a Murine Model of Iron Overload. Contrast Media & Molecular Imaging. 2019. 1–7. 5 indexed citations

Kihara, Makoto, et al.. (2017). Visualization of⁵⁷Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging. Journal of the American Society for Mass Spectrometry. 28(11). 2469–2475. 8 indexed citations

Ishikura, Nobuyuki, Mieko Yanagisawa, Toshiki Iwai, et al.. (2017). Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models. Anticancer Research. 37(2). 623–630. 6 indexed citations

Yamashita‐Kashima, Yoriko, et al.. (2017). Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model. Oncology Letters. 14(4). 4197–4205. 21 indexed citations

10.

Iwai, Toshiki, Masamichi Sugimoto, Suguru Harada, et al.. (2016). Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model. Oncology Reports. 36(2). 626–632. 14 indexed citations

11.

Sasaki, Yusuke, et al.. (2016). Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice. International Journal of Hematology. 103(3). 262–273. 9 indexed citations

12.

Furugaki, Koh, Toshiki Iwai, Keigo Yorozu, et al.. (2015). Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification. International Journal of Cancer. 138(4). 1024–1032. 31 indexed citations

13.

Sasaki, Yusuke, et al.. (2014). Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. International Journal of Hematology. 99(5). 561–569. 11 indexed citations

14.

Yamashita‐Kashima, Yoriko, Keigo Yorozu, Kaoru Hashizume, et al.. (2014). Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer. 17(4). 638–647. 33 indexed citations

15.

Sasaki, Yusuke, et al.. (2012). Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. International Journal of Hematology. 96(6). 692–700. 44 indexed citations

16.

Yamashita‐Kashima, Yoriko, Shigeyuki Iijima, Keigo Yorozu, et al.. (2011). Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research. 17(15). 5060–5070. 150 indexed citations

17.

Hirata, Michinori, Keigo Yorozu, Kenichi Serizawa, et al.. (2009). Nicorandil Improves Glomerular Injury in Rats With Mesangioproliferative Glomerulonephritis via Inhibition of Proproliferative and Profibrotic Growth Factors. Journal of Pharmacological Sciences. 111(1). 53–59. 22 indexed citations

18.

Adachi, Kenji, Masami Suzuki, Keigo Yorozu, et al.. (2003). Effects of Granulocyte Colony-Stimulating Factor (G-CSF) on Bleomycin-Induced Lung Injury of Varying Severity. Toxicologic Pathology. 31(6). 665–673. 20 indexed citations

19.

Katsume, Asao, Hiroyuki Saito, Yoshiki Yamada, et al.. (2002). ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE. Cytokine. 20(6). 304–311. 112 indexed citations

20.

Okada, Naoki, Hajime MIYAMOTO, Tatsunobu Yoshioka, et al.. (1997). Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(l) lysine-alginate membrane. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1360(1). 53–63. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact